ToDAY Compared To Spectramast® LC
A Non-inferiority Trial Comparing a First-Generation Cephalosporin with a Third-Generation Cephalosporin in the Treatment of Non-Severe Clinical Mastitis in Dairy Cows
Presentations
Proven Efficacy
Two treatments of ToDAY showed no difference in clinical and overall bacteriologic cure rates bacteriologic clinical cure rates when compared to five tubes of Spectramast® LC (ceftiofur hydrochloride).2
Think Positive
Intramammary mastitis treatment of Gram-positive infections is widely reported as beneficial,⁴ so those infections should be the focus of treatment.¹
Short Duration
Administering two syringes of ToDAY results in a short-duration milk discard of 108 hours' (4.5 days) time out-of-tank.
Learn more about treating infection vs. inflammation (PDF).
Milk that has been taken from animals during treatment and for 96 hours after the last treatment must not be used for food.
Treated animals must not be slaughtered for food until four days after the last treatment.
Administration of more than the prescribed dose may lead to residue of antibiotic in milk longer than 96 hours.
ToDAY should be administered with caution to subjects that have demonstrated some form of allergy, particularly to penicillin. Such reactions are rare; however, should they occur, consult your veterinarian.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Choosing a short-duration treatment protocol allows you to treat mastitis with fewer antibiotics than a five-day protocol, without sacrificing efficacy.2
1. Keefe G, MacDonald K, Cameron M. On-farm culture use experience and impact on antimicrobial use. University of Prince Edward Island, Charlottetown, PE, Canada.
2. Schukken YH, Zurakowski MJ, Rauch BJ, et al. Non-inferiority trial comparing a first-generation cephalosporin with a third-generation cephalosporin in the treatment of nonsevere clinical mastitis in dairy cows. J Dairy Sci 2013;96(10):6763–6774.
3. Nydam D, Virkler P, Capel M, et al. Pathogen-based treatment decisions for clinical mastitis, in Proceedings. NMC Regional Meeting 2015;1-4.
4. Hess JL, Neuder LM, Sears PM. Rethinking clinical mastitis therapy, in Proceedings. 42nd Annu Meet of the NCM 2003:372–373.
5. Sutherland SF. Novel syringe partial infusion, in Proceedings. National Mastitis Council 1989.
ToDAY® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. All other trademarks are the property of their respective owners. ©2025 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.
US-RUM-0025-2025